Immuno-oncology in triple-negative breast cancer
作者机构：Department of Obstetrics and GynecologyUniversity Medical Center MainzMainz 55131Germany
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2021年第7卷第1期
页 面：133-144页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Tumor infiltrating lymphocytes cancer-immunity-cycle immune checkpoint inhibitors vaccination,tumor-associated antigens neoantigens
摘 要：The immune system plays an important role in breast ***-negative breast cancer(TNBC)has a higher mutational load compared to other *** addition,higher levels of tumor-associated antigens suggests that immunotherapies are a promising treatment option especially for *** review discusses both the complexity of the immune system and the cancer immune-cell *** fact,a higher level of tumor-infiltrating lymphocytes is associated with an improved prognosis as well as a better response to chemotherapy in *** target structures within the cancer immune-cell cycle are the so-called“immune checkpoints.Immune checkpoint inhibitors(ICPi)block the interaction of certain cell surface proteins that serve as“brakesof immune *** studies have shown ICPi improved survival in early as well as advanced ***,this has the price of increasing,mainly,immune-mediated *** strengthen tumor-specific T cell-mediated immunity by“releasing the brakeof the immune *** combination with chemotherapy,ICPi are already approved for *** a further step,individualized vaccination strategies against tumor-associated neoantigens represent another promising approach.A liposome-formulated intravenous RNA vaccine encoding different tumor-associated antigens is currently being studied in TNBC and leads to neoantigen-specific immune *** novel strategies will improve the prognosis of patients with triple-negative breast cancer.
维普期刊数据库